IGCP567地震考古研究项目最新动态消息
"目录号: HY-14171
欢迎有对于地震考古研究和喇家遗址史前地震感兴趣的年轻朋友及时与我们联系
Metabolic Enzyme/ProteaseAutophagy-
Bexarotene (Targretin)是维甲酸X受体（RXR）激动剂，可作用于CTCL。
MEETINGS
相关产品
· On 22 February 2012 IGCP will celebrate its 40th Anniversary at the UNESCO Headquarters in Paris. Two of our co-leaders will actively participate at this meeting. Iain Stewart (University of Plymouth, U.K.) will focus on the importance of Geosciences for Society and moderate a debate on the prospective vision for the future of IGCP. Manuel Sintubin (Katholieke Universiteit Leuven, Belgium) will reflect on the role of IGCP in geohazard mitigation based on the success of IGCP567.
Cycloheximide-TAK-242-LY294002-3-Methyladenine-( )-JQ-1-SB 203580-永利总站，SP600125-U0126-Enzalutamide-Actinomycin D-Olaparib-Doxorubicin hydrochloride-Dorsomorphin dihydrochloride-Mitomycin C-Bortezomib-
生物活性
·At the 2012 Annual Meeting of the Seismological Society of America (17-19 April, 2012, San Diego, California): Earthquakes and Tsunamis at Caostal Archaeological Sites. You find details in the following announcement (pdf ). Abstract submission deadline is 11 January 2012.
Description
Bexarotene (Targretin) is a selective RXR agonist approved for the treatment of CTCL.IC50 value:Target: retinoid X receptorExposure of NSCLC cell lines to bexarotene as a single agent had modest growth inhibitory effects (at > 1 μM). However, exposure of several NSCLC lines to bexarotene (1–3 μM) produced significant decreases in the expression of EGFR, Her-2 and TGF mRNA and protein. EGF levels were also decreased to a much lesser degree.
·At the 34th International Geological Congress (IGC), from 2 to 10 August 2012 at Brisbane, Queensland, Australia a special session is convened by Patrick Nunn (Australia), Bruce McFadgen (New Zealand), Iain Stewart (U.K.) and Manuel Sintubin (Belgium) on Natural Hazards and Ancient Societies. Abstract submission deadline is 17 February 2012.
Clinical Trial
·In November 2012 we are furthermore planning an international workshop Shakin’ them off? Interdisciplinary perspectives on Minoan Earthquakes, convened by Simon Jusseret (Université Catholique de Louvain, Belgium) and Manuel Sintubin (Katholieke Universiteit Leuven, Belgium), which will take place in Leuven (Belgium).
Dartmouth-Hitchcock Medical Center-Bristol-Myers Squibb-Ligand Pharmaceuticals
Carcinoma, Non-small-cell Lung
For both conferences IGCP567 will most probably (depending on our funding) be able to offer travel grants.
August 2001
Phase 1-Phase 2
·At the EGU meeting (20-24 April 2012, Vienna, Austria) Matthieu Ferry (Géosciences Montpellier, France) and Kris Vanneste (ROB, Belgium) convene a session on Earthquake Geology. Abstract submission deadline is 17 January 2012.
Abramson Cancer Center of the University of Pennsylvania
·The 3rd Workshop on Paleoseismology and Archaeoseismology will be held in Morelia, Mexico from 1 to 8 November 2012. More information will follow soon on the http://www.acambay1912.org.
Acute Myeloid Leukemia
January 2008
PUBLICATIONS
Phase 2
Following our 2nd INQUA-IGCP567 International Workshop on Active Tectonics, Earthquake Geology, Archaeology and Engineering, held from 18 to 24 September 2011 in Corinth, Greece, Andreas Vött (University of Mainz, Germany) is preparing a special volume on in the Zeitschrift für Geomorphologie. This is a peer-review ISI-indexed journal and hosted up to now three special volumes on tsunamis. If you are interested to contribute to this volume, please contact Andreas Vött (voett@uni-mainz.de).
Georgetown University-Daiichi Sankyo Inc.
Solid Tumors-Lymphoma-Multiple Myeloma
International Geoscience Programme
IGCP 567 Earthquake Archaeology
December 2011
De wetenschap van de Aarde. Over een levende planeet
Phase 1
Dartmouth-Hitchcock Medical Center-Ligand Pharmaceuticals-Genentech, Inc.
Disclaimer: http://www.kuleuven.be/cwis/email_disclaimer.htm
Carcinoma, Non-small-cell Lung
December 2005
University of Virginia
Cushing's Disease
November 2008
Phase 1-Phase 2
The Cleveland Clinic
Alzheimer's Disease
February 2013
Phase 2
Dartmouth-Hitchcock Medical Center-Genentech, Inc.-Ligand Pharmaceuticals
Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus)
April 2003
Phase 1
Baylor Breast Care Center-National Cancer Institute (NCI)
Breast Cancer
September 2001
Phase 1
Dartmouth-Hitchcock Medical Center-Ligand Pharmaceuticals-Genentech, Inc.
Carcinoma, Non-small-cell Lung
August 2005
Phase 2
ReXceptor, Inc.
Alzheimer's Disease
August 2014
Phase 1
Valeant Pharmaceuticals International, Inc.
Refractory Cutaneous T-cell Lymphoma
December 2009
Phase 4
University College, London
Lymphoma
March 2008
Phase 2
Washington University School of Medicine
Leukemia, Myeloid, Acute
May 2010
Phase 1
Abramson Cancer Center of the University of Pennsylvania
AML-Acute Myeloid Leukemia
January 2004
Phase 1
M.D. Anderson Cancer Center-United States Department of Defense
Lung Cancer
November 2006
Phase 2
Boston University-Ligand Pharmaceuticals
Cutaneous T-Cell Lymphoma
December 2001
Phase 1-Phase 2
Beersheva Mental Health Center
Schizophrenia
November 2008
Phase 3
Millennium Pharmaceuticals, Inc.-Seattle Genetics, Inc.-Takeda
Primary Cutaneous Anaplastic Large Cell Lymphoma-Mycosis Fungoides-Cutaneous T-Cell Lymphoma
August 2012
Phase 3
Memorial Sloan Kettering Cancer Center-National Cancer Institute (NCI)-Tibotec Pharmaceutical Limited-M.D. Anderson Cancer Center-New York University School of Medicine-Hackensack University Medical Center-Roswell Park Cancer Institute
Lymphoma
November 2005
Phase 2
Vanderbilt University
Cutaneous T-cell Lymphoma-Mycosis Fungoides-Sezary Syndrome
June 2005
Phase 2
Beersheva Mental Health Center-Stanley Medical Research Institute
Schizophrenia
September 2005
Phase 3
University of Medicine and Dentistry of New Jersey-Ligand Pharmaceuticals-Rutgers, The State University of New Jersey
Psoriasis
November 2003
Phase 2
Spectrum Pharmaceuticals, Inc
Cutaneous T-cell Lymphoma-Mycosis Fungoides-Sezary Syndrome-Primary Cutaneous Anaplastic Large Cell Lymphoma
March 2010
编辑：历史 本文来源：Bexarotene
关键词：